News >

Adjuvant Ipilimumab Improves OS in High-Risk Melanoma

Brittany Cote
Published: Tuesday, Feb 18, 2020

Adjuvant treatment with ipilimumab (Yervoy), when given at a 3-mg/kg dose, was found to improve overall survival (OS) compared with high-dose interferon alfa (HDI) in patients with high-risk melanoma, according to results of the phase III E1609 trial.

“Immune-related AEs in the adjuvant setting may compromise therapeutic options in the event of recurrence. There were nonsignificant trends toward improvement in OS and RFS with [10 mg/kg of ipilimumab] versus HDI, which raises the question of whether increased toxicity with [10 mg/kg of ipilimumab] affected outcomes,” the authors stated. “The protocol had strict toxicity-specific criteria that mandated treatment delay for moderate immune-related AEs and discontinuation for more severe AEs.”
Tarhini AA, Lee SJ, Hodi FS, et al. Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609. J Clin Oncol. 2020;38(6):567-575. doi: 10.1200/JCO.19.01381.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x